Picard Medical Announces UCSF's First Heart Transplant Success
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 12 2026
0mins
Should l Buy PMI?
Picard Medical, parent company of SynCardia Systems, announced that University of California, San Francisco, UCSF, Health has successfully performed its first heart transplant in a patient who had previously been supported with the SynCardia Total Artificial Heart, marking an important clinical milestone in the treatment of advanced biventricular heart failure. UCSF Health is the U.S. News & World Report 2025-2026 top-ranked hospital in California. Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical Inc., commented, "This fifth case at UCSF highlights the continued clinical adoption of the SynCardia Total Artificial Heart at leading transplant centers and now has a corresponding successful heart transplantation. For patients in advanced biventricular failure, time is critical. The ability to stabilize and sustain these patients, so that they are also healthy enough for surgery until a suitable donor heart becomes available is central to our mission."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PMI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PMI
About PMI
Picard Medical, Inc. is a holding company that owns a 100% interest in SynCardia Systems, LLC (SynCardia). SynCardia is a medical technology company that manufactures and sells the only United States Food and Drug Administration (FDA) and Health Canada-approved implantable total artificial heart (SynCardia TAH). The SynCardia TAH is a biventricular replacement device that consists of the SynCardia TAH implant, an external pneumatic driver that delivers precisely calibrated pulses of air to drive the implant, and drivelines that connect the driver to the implant. The SynCardia TAH implant is a system that consists of two independent artificial ventricles which are powered by an external pneumatic driver. Each artificial ventricle is made of a semi-rigid polyurethane housing and a rigid polyurethane base, with a four-layer flexible polyurethane diaphragm separating the blood chamber from the air chamber.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Picard Medical Faces Class Action Lawsuit
- Fraud Allegations Unveiled: Robbins LLP has alerted investors that Picard Medical (PMI) is facing a class action lawsuit for allegedly engaging in a fraudulent stock promotion scheme related to securities transactions between September 2 and October 31, 2025, which could severely impact the company's reputation and stock price if proven true.
- Stock Price Crash: On October 24, 2025, Picard Medical's stock price plummeted by 70%, dropping from approximately $13.30 to $3.99 per share, and has since continued to decline to around $2.00, indicating extreme market concern regarding the company's financial health.
- Insider Trading Investigation: The lawsuit alleges that company executives and affiliates used offshore or nominee accounts for coordinated share dumping, failing to disclose false information and artificial trading activities to investors, which could lead to legal repercussions and further loss of investor trust.
- Shareholder Action Guidance: Affected shareholders can file to become lead plaintiffs in the class action by April 3, 2026, and even those who choose not to participate can still be eligible for recovery, highlighting potential flaws in corporate governance and the impact on shareholder rights.
See More
Multiple Companies Face Class Action Lawsuits
- Richtech Robotics Class Action: Richtech Robotics Inc. is facing allegations for failing to disclose its claimed relationship with Microsoft during the class period from January 27 to January 29, 2026, misleading investors about the company's prospects, with a lead plaintiff deadline of April 3, 2026.
- Picard Medical Fraud Allegations: Picard Medical, Inc. is accused of being involved in a fraudulent stock promotion scheme from September 2 to October 31, 2025, which included misinformation on social media and insider trading, with investors needing to file a lead plaintiff motion by April 3, 2026, to address potential losses.
- Plug Power Misrepresentation: Plug Power, Inc. is alleged to have overstated the availability of funds related to a DOE loan during the class period from January 17 to November 13, 2025, leading to investor misconceptions about future projects, with a lead plaintiff deadline of April 3, 2026.
- Legal Consultation Advisory: Affected investors are encouraged to contact The Law Offices of Frank R. Cruz to understand their legal rights and potential losses related to these class actions, ensuring they are informed about their options for participation.
See More
Picard Medical Investors Warned of Significant Losses
- Legal Investigation: Faruqi & Faruqi, LLP is investigating potential claims against Picard Medical (NYSE: PMI) and reminds investors to apply by April 13, 2026, to seek the role of lead plaintiff in a federal securities class action to protect their legal rights.
- Stock Price Plunge: On October 24, 2025, Picard Medical's shares plummeted from $13.20 to $5.31, a staggering drop of $7.89 or approximately 59.8%, marking one of the most significant single-day declines since the company's IPO.
- False Promotion Allegations: The lawsuit alleges that Picard Medical and its executives violated federal securities laws by engaging in fraudulent stock promotion schemes involving misinformation on social media and insider trading, severely undermining investor confidence and the company's reputation.
- Investor Rights Protection: Faruqi & Faruqi is seeking information from anyone aware of Picard Medical's conduct, including whistleblowers and former employees, to support affected investors and ensure their rights are protected in the legal proceedings.
See More
Picard Medical Securities Class Action Notice
- Class Action Notice: Rosen Law Firm reminds investors who purchased Picard Medical securities between September 2, 2025, and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to participate in the class action without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Picard Medical made materially false and misleading statements regarding its business and securities trading, failing to disclose a fraudulent stock promotion scheme and insider selling activities, which misled investors.
- Law Firm's Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and success in this field.
- Investor Advisory: Investors are advised to carefully select qualified law firms with a proven track record, avoiding those that merely act as intermediaries, to ensure effective legal representation and support in the class action.
See More
Class Action Lawsuit Reminder Against Picard Medical, Inc.
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Picard Medical, Inc. (NYSE American:PMI) for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between September 2, 2025, and October 31, 2025, with a deadline to contact the firm by April 3, 2026.
- False Statements Allegation: The complaint alleges that Picard made false and misleading statements during the class period, engaging in a manipulation scheme to fraudulently inflate its stock price, resulting in significant losses for investors once the truth was revealed.
- Opportunity for Loss Recovery: Investors are encouraged to join the lawsuit to recover their losses, with the Schall Law Firm specializing in securities class actions and representing investors globally, highlighting the importance of participation in the legal process.
- Legal Consultation Services: The Schall Law Firm offers free legal consultations, allowing investors to reach out via phone or email to understand their rights and the steps to participate in the class action, ensuring they receive necessary legal support before class certification.
See More
Picard Medical Securities Class Action Notice Issued
- Class Action Initiation: Rosen Law Firm reminds investors who purchased Picard Medical (NYSE American: PMI) securities between September 2 and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Picard Medical made materially false and misleading statements during the class period, failing to disclose significant adverse facts about its business and securities trading, which led to investor losses.
- Fraudulent Activities Uncovered: Specific allegations include involvement in a fraudulent stock promotion scheme via social media misinformation and insiders using offshore accounts to manipulate share prices, severely impacting investor perceptions of the company's prospects.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and success in this field.
See More
Picard Medical Faces Class Action Lawsuit
- Fraud Allegations Unveiled: Robbins LLP has alerted investors that Picard Medical (PMI) is facing a class action lawsuit for allegedly engaging in a fraudulent stock promotion scheme related to securities transactions between September 2 and October 31, 2025, which could severely impact the company's reputation and stock price if proven true.
- Stock Price Crash: On October 24, 2025, Picard Medical's stock price plummeted by 70%, dropping from approximately $13.30 to $3.99 per share, and has since continued to decline to around $2.00, indicating extreme market concern regarding the company's financial health.
- Insider Trading Investigation: The lawsuit alleges that company executives and affiliates used offshore or nominee accounts for coordinated share dumping, failing to disclose false information and artificial trading activities to investors, which could lead to legal repercussions and further loss of investor trust.
- Shareholder Action Guidance: Affected shareholders can file to become lead plaintiffs in the class action by April 3, 2026, and even those who choose not to participate can still be eligible for recovery, highlighting potential flaws in corporate governance and the impact on shareholder rights.
See More
Multiple Companies Face Class Action Lawsuits
- Richtech Robotics Class Action: Richtech Robotics Inc. is facing allegations for failing to disclose its claimed relationship with Microsoft during the class period from January 27 to January 29, 2026, misleading investors about the company's prospects, with a lead plaintiff deadline of April 3, 2026.
- Picard Medical Fraud Allegations: Picard Medical, Inc. is accused of being involved in a fraudulent stock promotion scheme from September 2 to October 31, 2025, which included misinformation on social media and insider trading, with investors needing to file a lead plaintiff motion by April 3, 2026, to address potential losses.
- Plug Power Misrepresentation: Plug Power, Inc. is alleged to have overstated the availability of funds related to a DOE loan during the class period from January 17 to November 13, 2025, leading to investor misconceptions about future projects, with a lead plaintiff deadline of April 3, 2026.
- Legal Consultation Advisory: Affected investors are encouraged to contact The Law Offices of Frank R. Cruz to understand their legal rights and potential losses related to these class actions, ensuring they are informed about their options for participation.
See More
Picard Medical Investors Warned of Significant Losses
- Legal Investigation: Faruqi & Faruqi, LLP is investigating potential claims against Picard Medical (NYSE: PMI) and reminds investors to apply by April 13, 2026, to seek the role of lead plaintiff in a federal securities class action to protect their legal rights.
- Stock Price Plunge: On October 24, 2025, Picard Medical's shares plummeted from $13.20 to $5.31, a staggering drop of $7.89 or approximately 59.8%, marking one of the most significant single-day declines since the company's IPO.
- False Promotion Allegations: The lawsuit alleges that Picard Medical and its executives violated federal securities laws by engaging in fraudulent stock promotion schemes involving misinformation on social media and insider trading, severely undermining investor confidence and the company's reputation.
- Investor Rights Protection: Faruqi & Faruqi is seeking information from anyone aware of Picard Medical's conduct, including whistleblowers and former employees, to support affected investors and ensure their rights are protected in the legal proceedings.
See More
Picard Medical Securities Class Action Notice
- Class Action Notice: Rosen Law Firm reminds investors who purchased Picard Medical securities between September 2, 2025, and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to participate in the class action without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Picard Medical made materially false and misleading statements regarding its business and securities trading, failing to disclose a fraudulent stock promotion scheme and insider selling activities, which misled investors.
- Law Firm's Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and success in this field.
- Investor Advisory: Investors are advised to carefully select qualified law firms with a proven track record, avoiding those that merely act as intermediaries, to ensure effective legal representation and support in the class action.
See More
Class Action Lawsuit Reminder Against Picard Medical, Inc.
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Picard Medical, Inc. (NYSE American:PMI) for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between September 2, 2025, and October 31, 2025, with a deadline to contact the firm by April 3, 2026.
- False Statements Allegation: The complaint alleges that Picard made false and misleading statements during the class period, engaging in a manipulation scheme to fraudulently inflate its stock price, resulting in significant losses for investors once the truth was revealed.
- Opportunity for Loss Recovery: Investors are encouraged to join the lawsuit to recover their losses, with the Schall Law Firm specializing in securities class actions and representing investors globally, highlighting the importance of participation in the legal process.
- Legal Consultation Services: The Schall Law Firm offers free legal consultations, allowing investors to reach out via phone or email to understand their rights and the steps to participate in the class action, ensuring they receive necessary legal support before class certification.
See More
Picard Medical Securities Class Action Notice Issued
- Class Action Initiation: Rosen Law Firm reminds investors who purchased Picard Medical (NYSE American: PMI) securities between September 2 and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Picard Medical made materially false and misleading statements during the class period, failing to disclose significant adverse facts about its business and securities trading, which led to investor losses.
- Fraudulent Activities Uncovered: Specific allegations include involvement in a fraudulent stock promotion scheme via social media misinformation and insiders using offshore accounts to manipulate share prices, severely impacting investor perceptions of the company's prospects.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and success in this field.
See More
